FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

스택 라이브러리

Stubborn Fat Protocol

Fat Lossbeginner

78

상호작용

78
Share
펩타이드

2

일 평균 mcg

100,300

수준

beginner

추가됨

May 17, 2026

개요

The Stubborn Fat Protocol combines AOD-9604 with 5-Amino-1MQ to address fat deposits that resist conventional diet and exercise interventions. AOD-9604, the modified GH fragment (177-191), directly stimulates lipolysis in adipose tissue by activating beta-3 adrenergic receptor pathways and inhibiting lipogenesis without the metabolic side effects of full-length growth hormone. Its mechanism specifically targets adipocytes in a way that mimics GH''s fat-mobilizing action while avoiding its glucose-raising and IGF-1-stimulating properties. 5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that is overexpressed in adipose tissue of obese individuals. NNMT regulates cellular energy expenditure through the NAD+ salvage pathway — when NNMT is overactive, it depletes SAM (S-adenosylmethionine) and reduces NAD+ availability, effectively slowing cellular metabolism. By inhibiting NNMT, 5-Amino-1MQ increases intracellular NAD+ and SAM levels, revving up metabolic rate within fat cells and promoting their energy expenditure rather than energy storage. The combination addresses stubborn fat through two independent mechanisms: AOD-9604 directly stimulates fat cell lipolysis (breaking triglycerides into free fatty acids for oxidation), while 5-Amino-1MQ increases the metabolic rate of adipocytes so they burn more energy. Stubborn fat areas (lower abdomen, love handles, thighs) typically have higher alpha-2 adrenergic receptor density and lower blood flow, making them resistant to catecholamine-driven fat mobilization. This dual approach bypasses some of these limitations. The protocol is classified as beginner-friendly due to its simplicity (one injection, one oral dose daily), though users should understand that both compounds require further human research.

용량 프로토콜

AOD-9604

Every day· subcutaneous

AOD-9604에 대한 자세한 내용 →

300 mcg

1회 용량당

100,000 mcg

1회 용량당

목표 및 증거

Fat lossMetabolismStubborn fatAdipocyte reductionEnergy
증거 등급:동물 연구

경고

  • AOD-9604 remains FDA Category 2 (restricted) as of July 2026. 5-Amino-1MQ is a research chemical with limited human data. Both require further study.

Comments

Sign in to join the discussion

주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.